Is neo-adjuvant chemotherapy a "waiver" of extensive upper abdominal surgery in advanced epithelial ovarian cancer?

Annals of Surgical Oncology

Volumn 18, Issue 13, 2011, Pages 3824-3827

  Kang, Sokbom ^a   Jong, Yoo Heon ^a   Hwang, Jong Ha ^a   Lim, Myong Cheol ^a   Seo, Sang Soo ^a   Yoo, Chong Woo ^a   Park, Sang Yoon ^a  

^a National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; TOPOTECAN;

ABDOMINAL CANCER; ABDOMINAL SURGERY; ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; ARTICLE; BLEEDING; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; SURGICAL APPROACH; SURGICAL TECHNIQUE;

ABDOMINAL NEOPLASMS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYSTADENOCARCINOMA, SEROUS; FEMALE; FOLLOW-UP STUDIES; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PACLITAXEL; PATIENT SELECTION; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 82955212973     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1830-0     Document Type: Article

References (18)

1. A Jemal T Murray E Ward A Samuels RC Tiwari A Ghafoor, et al. 2005 Cancer statistics, 2005 CA Cancer J Clin. 55 10 30 15661684 10.3322/canjclin.55.1.10 (Pubitemid 40310185)
2. RE Bristow RS Tomacruz DK Armstrong EL Trimble FJ Montz 2002 Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol. 20 1248 1259 11870167 10.1200/JCO.20.5.1248 (Pubitemid 34177431)
3. KK Shih DS Chi 2010 Maximal cytoreductive effort in epithelial ovarian cancer surgery J Gynecol Oncol. 21 75 80 20613895 10.3802/jgo.2010.21.2.75
4. RF Ozols BN Bundy BE Greer JM Fowler D Clarke-Pearson RA Burger, et al. 2003 Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol. 21 3194 3200 12860964 10.1200/JCO.2003.02.153 1:CAS:528:DC%2BD2cXps1aktbk%3D (Pubitemid 46606249)
5. S Kang BH Nam 2009 Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies Ann Surg Oncol. 16 2315 2320 19517192 10.1245/s10434-009-0558-6
6. PE Schwartz TJ Rutherford JT Chambers JN McAlpine M Azodi TJ Rutherford, et al. 1999 Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival Gynecol Oncol. 72 93 99 9889037 10.1006/gyno.1998.5236 1:CAS:528:DyaK1MXhtVyktbo%3D (Pubitemid 29045454)
7. I Vergote CG Trope F Amant GB Kristensen T Ehlen N Johnson, et al. 2010 Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med. 363 943 953 20818904 10.1056/NEJMoa0908806 1:CAS:528: DC%2BC3cXhtFWjt7fF
8. PE Schwartz 2002 Neoadjuvant chemotherapy for the management of ovarian cancer Best Pract Res Clin Obstet Gynaecol. 16 585 596 12413936 10.1053/beog.2002.0304 (Pubitemid 41123408)
9. I Vergote T van Gorp F Amant P Neven P Berteloot 2005 Neoadjuvant chemotherapy for ovarian cancer Oncology (Williston Park) 19 1615 1622 discussion 1623-30 (Pubitemid 46511211)
10. T Van Gorp F Amant P Neven P Berteloot K Leunen I Vergote 2007 The role of neoadjuvant chemotherapy versus primary surgery in the management of stage III ovarian cancer Cancer Treat Res. 134 387 402 17633068
11. F Kayikcioglu MF Kose N Boran E Calişkan G Tulunay 2001 Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma Int J Gynecol Cancer. 11 466 470 11906550 10.1046/j.1525-1438.2001. 01064.x 1:STN:280:DC%2BD387nt1GjsQ%3D%3D (Pubitemid 34024805)
12. SJ Lee BG Kim JW Lee CS Park JH Lee DS Bae 2006 Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery J Obstet Gynaecol Res. 32 99 106 16445534 10.1111/j.1447-0756.2006.00359.x 1:CAS:528:DC%2BD28XjtlWrtr8%3D
13. M Baekelandt 2003 The potential role of neoadjuvant chemotherapy in advanced ovarian cancer Int J Gynecol Cancer 13 Suppl 2 163 168 14656274 10.1111/j.1525-1438.2003.13354.x (Pubitemid 38228759)
14. A Inciura A Simavicius E Juozaityte J Kurtinaitis R Nadisauskiene E Svedas, et al. 2006 Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients BMC Cancer 6 153 16759398 10.1186/1471-2407-6-153 (Pubitemid 44202789)
15. T Giannopoulos S Butler-Manuel A Taylor N Ngeh H Thomas 2006 Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma Eur J Gynaecol Oncol. 27 25 28 16550963 1:STN:280: DC%2BD287mtFyitg%3D%3D
16. GD Aletti EL Eisenhauer A Santillan A Axtell G Aletti C Holschneider, et al. 2011 Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment Gynecol Oncol. 120 23 28 20933255 10.1016/j.ygyno.2010.09.010
17. GD Aletti SC Dowdy KC Podratz WA Cliby 2007 Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer Am J Obstet Gynecol 197 676 e1 676 e7 10.1016/j.ajog.2007.10.495 (Pubitemid 350166287)
18. S Kang TJ Kim BH Nam SS Seo BG Kim DS Bae, et al. 2010 Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis J Surg Oncol. 101 13 17 20025071 10.1002/jso.21398 1:CAS:528:DC%2BC3cXhsVyktLo%3D